Synapse - Carol Aghajanian

Results (615)

Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes

Journal Article

Praiss, A. M.; White, C.; Iasonos, A.; Selenica, P.; Zivanovic, O.; Chi, D. S.; Abu-Rustum, N. R.; Weigelt, B.; Aghajanian, C.; Girshman, J.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival

Journal Article

Kahn, R. M.; Selenica, P.; Boerner, T.; Roche, K. L.; Xiao, Y.; Sia, T. Y.; Maio, A.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Radiation quality and workflow in NRG GY017: Anti PD-L1 (atezolizumab) as an immune primer or concurrently with RT for node positive locally advanced cervical cancer

Meeting Abstract

Mayadev, J.; Deng, W.; Zamarin, D.; Lankes, H.; Kim, H.; Chino, J.; Banberry, B.; Sherry, N.; Ghamande, S.; Ferguson, C.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

The genomic landscape of distant metastatic endometrial cancer

Meeting Abstract

Zammarrelli, B.; Nandakumar, S.; Kertowidjojo, E.; Nguygen, B.; Paula, A. D.; Rios-Doria, E.; Smith, S.; Momeni-Boroujeni, A.; Aghajanian, C.; Mueller, J.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour brca1/2 mutation: Results from the DUO-O/ENGOT-OV46/AGO-OVAR 23/GOG-3025 trial

Meeting Abstract

Marth, C.; Park-Simon, T. W.; Aghajanian, C.; Reuss, A.; Nishio, S.; Lim, M. C.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Sabatier, R.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

Efficacy and safety of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy

Meeting Abstract

Grisham, R.; Aghajanian, C.; Van Nieuwenhuysen, E.; Rodrigues, M.; Ring, K.; Santin, A.; Colombo, N.; Prendergast, E.; Thaker, P.; Moore, K.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

Initial Efficacy and Safety Results from ENGOT-Ov60/GOG-3052/ramp 201: A phase 2 study of avutometinib (vs-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Meeting Abstract

Banerjee, S. N.; Ring, K. L.; Van Niewenhuysen, E.; Fabbro, M.; Aghajanian, C.; Oaknin, A.; Colombo, N.; Santin, A. D.; Clamp, A. R.; Moore, K. N.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

Germline pathogenic variants and genetic counseling by ancestry in patients with epithelial ovarian cancer

Journal Article

Sia, T. Y.; Maio, A.; Kemel, Y. M.; Arora, K. S.; Gordhandas, S. B.; Kahn, R. M.; Salo-Mullen, E. E.; Sheehan, M. A.; Tejada, P. R.; Bandlamudi, C.; more...
JCO Precision Oncology (2023)

Fulltext@MSK | Save

Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial